Chang Nai-Wen, Huang Yi-Ping
Department of Biochemistry, College of Medicine, China Medical University, Taichung 404, Taiwan.
Department of Physiology, College of Medicine, China Medical University, Taichung 404, Taiwan.
Biomedicine (Taipei). 2019 Dec;9(4):27. doi: 10.1051/bmdcn/2019090427. Epub 2019 Nov 14.
The activation of peroxisome proliferator-activated receptor alpha (PPARα) has been shown to reprogram tumor metabolism and exhibits great potential for treating anti-oral tumorigenesis.
In this study, we used a pathway-based strategy to explore possible functional pathways involved in the anticancer activity of PPARα in oral cancer cells through next-generation sequencing (NGS) and bioinformatic approaches.
We found that 3919 genes were upregulated and 1060 genes were downregulated through PPARα activation. These genes were mainly involved in the proteasomal, mRNA surveillance, spliceosomal, RNA transport, and RNA degradation pathways, as indicated by GO and KEGG enrichment analysis. Importantly, a total of 13 upregulated genes in the RNA degradation pathway were identified including 3 core exosome factor genes (RRP43, RRP42, and CSL4), 2 TRAMP complex genes (TRF4 and Mtr4), 2 exosome cofactor genes (RRP6 and MPP6), 2 CCR4-NOT complex genes (CNOT2 and CNOT3), 2 Ski complex genes (SKI2 and Ski3), 1 decapping complex gene (EDC4), and 1 gene involved in 5' exoribonuclease activity (XRN1).
Our findings suggest that the activation of PPARα to upregulate the RNA degradation pathway might provide a new strategy for oral cancer treatment.
过氧化物酶体增殖物激活受体α(PPARα)的激活已被证明可重编程肿瘤代谢,并在治疗抗口腔肿瘤发生方面具有巨大潜力。
在本研究中,我们采用基于通路的策略,通过下一代测序(NGS)和生物信息学方法,探索PPARα在口腔癌细胞中的抗癌活性所涉及的可能功能通路。
我们发现通过PPARα激活,3919个基因上调,1060个基因下调。GO和KEGG富集分析表明,这些基因主要参与蛋白酶体、mRNA监测、剪接体、RNA转运和RNA降解通路。重要的是,在RNA降解通路中总共鉴定出13个上调基因,包括3个核心外泌体因子基因(RRP43、RRP42和CSL4)、2个TRAMP复合体基因(TRF4和Mtr4)、2个外泌体辅助因子基因(RRP6和MPP6)、2个CCR4 - NOT复合体基因(CNOT2和CNOT3)、2个Ski复合体基因(SKI2和Ski3)、1个去帽复合体基因(EDC4)和1个参与5'外切核糖核酸酶活性的基因(XRN1)。
我们的研究结果表明,激活PPARα以上调RNA降解通路可能为口腔癌治疗提供一种新策略。